The word 'lithium' stopped me cold the first time it came up in the context of supplements — because most people only know it as a heavy-duty psychiatric drug. Understanding that nutritional lithium orotate is a completely different thing, used at a fraction of the dose, took some real digging. If you've felt the same knee-jerk hesitation, you're not alone — and that hesitation is actually a sign you're asking the right questions.
Learn more about Rose →Most people associate lithium exclusively with lithium carbonate, the prescription medication used at high doses to treat bipolar disorder — but lithium is actually a trace mineral found naturally in soil, water, and many foods including grains, vegetables, and dairy. Lithium orotate is a specific salt form where lithium is bound to orotic acid, a naturally occurring compound, which is thought to improve cellular absorption at much lower doses. The nutritional doses being discussed in integrative medicine contexts — typically 1 to 10 mg of elemental lithium — are a world away from the 300–900 mg doses used in psychiatric prescribing.
Estrogen plays a well-documented role in modulating serotonin, dopamine, and GABA pathways — the same neurotransmitter systems involved in mood regulation, emotional resilience, and anxiety response. When estrogen levels begin fluctuating and declining in perimenopause, these systems can become dysregulated in ways that produce symptoms ranging from irritability and low mood to outright depression and panic. Lithium, even at low doses, has been studied for its ability to support similar neurotransmitter balance and protect neurons from oxidative stress, which is why researchers are beginning to ask whether it could play a supportive role during this specific hormonal transition.
Several large epidemiological studies across Japan, the United States, Austria, and Greece have found that regions with higher naturally occurring lithium levels in drinking water tend to show lower rates of suicide, depression, and violent behavior in the general population. A landmark Japanese study published in the British Journal of Psychiatry in 2009 found a statistically significant inverse relationship between tap water lithium levels and suicide rates across 18 municipalities. While these are observational studies that cannot prove causation, the consistency of the finding across geographies has given researchers genuine reason to study lithium's role in everyday brain health — not just acute psychiatric illness.
Brain-derived neurotrophic factor, or BDNF, is a protein that supports the survival, growth, and maintenance of neurons, and it is often described as the brain's own fertilizer for mood and cognitive resilience. Estrogen is one of the key regulators of BDNF expression, which means that as estrogen declines during perimenopause, BDNF levels can fall — contributing to low mood, brain fog, and a reduced capacity for emotional recovery. Lithium has been shown in multiple studies to increase BDNF expression and activate neuroprotective signaling pathways, which is part of why researchers studying cognitive aging and mood disorders are now paying closer attention to it.
The reason lithium orotate specifically attracts interest — rather than other lithium salts — is the hypothesis that the orotate carrier molecule facilitates more efficient transport across the blood-brain barrier and into cells, allowing meaningful neurological effects at doses far lower than prescription lithium carbonate. This mechanism is plausible given orotic acid's established role in cellular metabolism, but rigorous pharmacokinetic studies comparing lithium orotate directly to lithium carbonate in humans are still limited. Most of what is known about orotate's transport advantages comes from earlier animal studies and biochemical reasoning rather than definitive human clinical trials.
One of the most important distinctions to understand is that the well-known toxicity concerns associated with prescription lithium — including kidney damage, thyroid dysfunction, and the need for blood monitoring — are associated with the high therapeutic doses used in bipolar disorder treatment, where serum lithium levels must be carefully maintained in a narrow window. At the nutritional doses of elemental lithium being discussed in the orotate context, typically under 10 mg per day, those toxicity thresholds are not being approached, and the mineral is consumed at levels comparable to what some populations naturally ingest through food and water. That said, this is not a free pass: anyone with kidney disease, thyroid conditions, or who is taking medications that affect lithium clearance should consult a clinician before using any lithium supplement.
Beyond mood, one of the most scientifically active areas of lithium research is its potential role in protecting against neurodegenerative conditions, including Alzheimer's disease, which disproportionately affects women — a fact that is increasingly being linked to the loss of estrogen's neuroprotective effects at menopause. Lithium has been shown to inhibit an enzyme called GSK-3 beta, which is involved in the abnormal tau protein phosphorylation seen in Alzheimer's pathology, and several small clinical trials in people with mild cognitive impairment have shown promising results with micro-dose lithium. The perimenopause window is being studied as a potentially critical period for neuroprotective intervention, which is why some researchers are arguing this conversation is worth having now rather than later.
Here is the honest gap in the evidence: despite the biologically coherent rationale and the promising epidemiological and mechanistic data, there are currently no published randomized controlled trials specifically examining lithium orotate supplementation in perimenopausal or menopausal women for mood or cognitive outcomes. Most of the human research on low-dose lithium has been conducted in elderly populations for dementia prevention, or in people with existing mood disorders, and the orotate form specifically has been studied far less than lithium carbonate. This means that enthusiasm in integrative medicine circles is running ahead of the clinical evidence base, and women considering it deserve to know that clearly.
For women whose perimenopause mood symptoms are significantly affecting quality of life, the treatments with the strongest evidence base remain hormone therapy, certain antidepressants studied specifically in this population, and structured behavioral interventions like cognitive behavioral therapy adapted for menopause. Lithium orotate, at this stage, is best understood as a supplement with a biologically plausible and intriguing rationale — not a replacement for those approaches, and not something to use as a reason to avoid a conversation with a knowledgeable clinician. The most balanced framing is: the science is genuinely interesting, the safety profile at nutritional doses appears reasonable for most healthy women, and the field needs well-designed trials to move this from 'promising' to 'recommended.'
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.